Information Provided By: 
Fly News Breaks for July 11, 2018
MYGN
Jul 11, 2018 | 07:23 EDT
Morgan Stanley analyst Steve Beuchaw upgraded Myriad Genetics to Overweight from Equal Weight after raising his estimates by more than 20% given his view that its earnings profile is "dramatically changing." He said the core HCT business is showing more durability, with volumes returning to growth and price declines slowing, while the acquisitions of Assurex and Counsyl are diversifying the company into higher growth and improving average selling price testing markets. Beuchaw raised his price target on Myriad shares to $55 from $35.
News For MYGN From the Last 2 Days
There are no results for your query MYGN
